Latest:
FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life
Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Benjamin L. Schlechter, MD
Instructor, Medicine, Harvard Medical School and an attending Physician, Medical Oncology, Dana-Farber Cancer Institute.
Latest:
Dr Schlechter on the Safety of Botensilimab Plus Balstilimab in Pretreated MSS CRC
Benjamin L. Schlechter, MD, discusses safety with botensilimab plus balstilimab in MSS CRC.
Gerhard Hildebrandt, MD, FACP
Latest:
Reflecting on Research Highlights in Acute Leukemia and Multiple Myeloma With Drs Hildebrandt and Baljevic
Gerhard Hildebrandt, MD, FACP, and Muhamed Baljevic, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in acute leukemia and multiple myeloma presented during the 2025 ASH Annual Meeting & Exposition.
Teresa Petrella, MD, MHSc, FRCPC
Teresa Petrella, MD, MHSc, FRCPC, is a medical oncologist at the Sunnybrook Odette Cancer Centre in Toronto, Canada, and an associate professor at the University of Toronto.
Latest:
Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma
Teresa Petrella, MD, MHSc, FRCPC, discusses considerations in selecting frontline therapy for patients with metastatic melanoma.
Sangeeta Goswami, MD, PhD
Sangeeta Goswami, MD, PhD, of the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, of The University of Texas MD Anderson Cancer Center
Latest:
Dr. Goswami's Oncology Journey: Patient-centric Science and Mentorship Stories
Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.
Grant Morgan, PhD, PMP
Latest:
Highlighting the Efficacy of VaxEffect With Immune Response to COVID-19 Vaccines
Renold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.
Armeen Mahvash, MD
Armeen Mahvash, MD is a Professor in the Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.
Latest:
FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD
Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.
Bruno R. Bastos, MD, Miami Cancer Institute
Latest:
Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Paul Stockhammer, MD, PhD
Latest:
Dr Stockhammer on Gene Alterations and Poor Outcomes in EGFR-Mutant Lung Cancer
Paul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.
Amer Zeidan, MBBS
Amer Zeidan, MBBS, is director of Early Therapeutics Research, director of the Leukemia and Myeloid Malignancies Program, assistant medical director of the Clinical Trials Office, and co-leader of the Leukemia and Myeloid Malignancies Clinical Research Team at Yale Cancer Center; as well as chief of the Division of Hematologic Malignancies and a professor of internal medicine (hematology) at Yale School of Medicine
Latest:
An All-Oral Regimen of Decitabine-Cedazuridine (DEC-C) Plus Venetoclax (VEN) in Patients With Newly Diagnosed AML Ineligible for Intensive Induction Chemotherapy: Results From a Phase 2 Cohort of 101 Patients
Presented by Amer Zeidan, MBBS, this OncLive Rapid Readout highlights results from the phase 2 ASCERTAIN-V trial, in which an all-oral regimen of decitabine-cedazuridine plus venetoclax achieved a 46.5% complete response rate and a median overall survival of 15.5 months in newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.